Glaucoma is the leading cause of preventable, irreversible blindness world-wide. The disease can remain asymptomatic until severe, and an estimated 50%-90% of people with glaucoma remain undiagnosed. Thus, glaucoma screening is recommended for early detection and treatment. A cost-effective tool to detect glaucoma could expand healthcare access to a much larger patient population, but such a tool is currently unavailable. We trained a deep learning (DL) algorithm using a retrospective dataset of 58,033 images, assessed for gradability, glaucomatous optic nerve head (ONH) features, and referable glaucoma risk. The resultant algorithm was validated using 2 separate datasets. For referable glaucoma risk, the algorithm had an AUC of 0.940 (95%CI, 0.922-0.955) in validation dataset "A" (1,205 images, 1 image/patient; 19% referable where images were adjudicated by panels of fellowship-trained glaucoma specialists) and 0.858 (95% CI, 0.836-0.878) in validation dataset "B" (17,593 images from 9,643 patients; 9.2% referable where images were from the Atlanta Veterans Affairs Eye Clinic diabetic teleretinal screening program using clinical referral decisions as the reference standard). Additionally, we found that the presence of vertical cup-to-disc ratio >= 0.7, neuroretinal rim notching, retinal nerve fiber layer defect, and bared circumlinear vessels contributed most to referable glaucoma risk assessment by both glaucoma specialists and the algorithm. Algorithm AUCs ranged between 0.608-0.977 for glaucomatous ONH features. The DL algorithm was significantly more sensitive than 6 of 10 graders, including 2 of 3 glaucoma specialists, with comparable or higher specificity relative to all graders. A DL algorithm trained on fundus images alone can detect referable glaucoma risk with higher sensitivity and comparable specificity to eye care providers.
Diabetic eye disease is one of the fastest growing causes of preventable blindness. With the advent of anti-VEGF (vascular endothelial growth factor) therapies, it has become increasingly important to detect center-involved diabetic macular edema. However, center-involved diabetic macular edema is diagnosed using optical coherence tomography (OCT), which is not generally available at screening sites because of cost and workflow constraints. Instead, screening programs rely on the detection of hard exudates as a proxy for DME on color fundus photographs, often resulting in high false positive or false negative calls. To improve the accuracy of DME screening, we trained a deep learning model to use color fundus photographs to predict DME grades derived from OCT exams. Our "OCT-DME" model had an AUC of 0.89 (95% CI: 0.87-0.91), which corresponds to a sensitivity of 85% at a specificity of 80%. In comparison, three retinal specialists had similar sensitivities (82-85%), but only half the specificity (45-50%, p<0.001 for each comparison with model). The positive predictive value (PPV) of the OCT-DME model was 61% (95% CI: 56-66%), approximately double the 36-38% by the retina specialists. In addition, we used saliency and other techniques to examine how the model is making its prediction. The ability of deep learning algorithms to make clinically relevant predictions that generally require sophisticated 3D-imaging equipment from simple 2D images has broad relevance to many other applications in medical imaging.
Deep learning algorithms have been used to detect diabetic retinopathy (DR) with specialist-level accuracy. This study aims to validate one such algorithm on a large-scale clinical population, and compare the algorithm performance with that of human graders. 25,326 gradable retinal images of patients with diabetes from the community-based, nation-wide screening program of DR in Thailand were analyzed for DR severity and referable diabetic macular edema (DME). Grades adjudicated by a panel of international retinal specialists served as the reference standard. Across different severity levels of DR for determining referable disease, deep learning significantly reduced the false negative rate (by 23%) at the cost of slightly higher false positive rates (2%). Deep learning algorithms may serve as a valuable tool for DR screening.
Diabetic retinopathy (DR) and diabetic macular edema are common complications of diabetes which can lead to vision loss. The grading of DR is a fairly complex process that requires the detection of fine features such as microaneurysms, intraretinal hemorrhages, and intraretinal microvascular abnormalities. Because of this, there can be a fair amount of grader variability. There are different methods of obtaining the reference standard and resolving disagreements between graders, and while it is usually accepted that adjudication until full consensus will yield the best reference standard, the difference between various methods of resolving disagreements has not been examined extensively. In this study, we examine the variability in different methods of grading, definitions of reference standards, and their effects on building deep learning models for the detection of diabetic eye disease. We find that a small set of adjudicated DR grades allows substantial improvements in algorithm performance. The resulting algorithm's performance was on par with that of individual U.S. board-certified ophthalmologists and retinal specialists.
Refractive error, one of the leading cause of visual impairment, can be corrected by simple interventions like prescribing eyeglasses. We trained a deep learning algorithm to predict refractive error from the fundus photographs from participants in the UK Biobank cohort, which were 45 degree field of view images and the AREDS clinical trial, which contained 30 degree field of view images. Our model use the "attention" method to identify features that are correlated with refractive error. Mean absolute error (MAE) of the algorithm's prediction compared to the refractive error obtained in the AREDS and UK Biobank. The resulting algorithm had a MAE of 0.56 diopters (95% CI: 0.55-0.56) for estimating spherical equivalent on the UK Biobank dataset and 0.91 diopters (95% CI: 0.89-0.92) for the AREDS dataset. The baseline expected MAE (obtained by simply predicting the mean of this population) was 1.81 diopters (95% CI: 1.79-1.84) for UK Biobank and 1.63 (95% CI: 1.60-1.67) for AREDS. Attention maps suggested that the foveal region was one of the most important areas used by the algorithm to make this prediction, though other regions also contribute to the prediction. The ability to estimate refractive error with high accuracy from retinal fundus photos has not been previously known and demonstrates that deep learning can be applied to make novel predictions from medical images. Given that several groups have recently shown that it is feasible to obtain retinal fundus photos using mobile phones and inexpensive attachments, this work may be particularly relevant in regions of the world where autorefractors may not be readily available.
Each year, the treatment decisions for more than 230,000 breast cancer patients in the U.S. hinge on whether the cancer has metastasized away from the breast. Metastasis detection is currently performed by pathologists reviewing large expanses of biological tissues. This process is labor intensive and error-prone. We present a framework to automatically detect and localize tumors as small as 100 x 100 pixels in gigapixel microscopy images sized 100,000 x 100,000 pixels. Our method leverages a convolutional neural network (CNN) architecture and obtains state-of-the-art results on the Camelyon16 dataset in the challenging lesion-level tumor detection task. At 8 false positives per image, we detect 92.4% of the tumors, relative to 82.7% by the previous best automated approach. For comparison, a human pathologist attempting exhaustive search achieved 73.2% sensitivity. We achieve image-level AUC scores above 97% on both the Camelyon16 test set and an independent set of 110 slides. In addition, we discover that two slides in the Camelyon16 training set were erroneously labeled normal. Our approach could considerably reduce false negative rates in metastasis detection.